Novogen Announces Filing of Key Patent Application

Please select the service you want to use:

• Newsvine
• Digg
• Delicious
• StumbleUpon
• Technorati
• Buzz
• Favorites
• Google Reader

5 February 2013

ASX RELEASE

Novogen Announces Filing of Key Patent Application

Novogen is pleased to announce the filing of a provisional patent application

covering the novel technology associated with the manufacture and use of it new

class of molecules referred to as `super-benzopyrans'.

The invention is based on technology that Novogen acquired when it purchased

Triaxial Pharmaceuticals Pty Ltd on 7 Dec 2012. Triaxial had developed a novel

manufacturing process that involved chemically `bending' molecules to allow the

insertion of atoms not previously possible. The Triaxial goal was the ability to
design and build molecules to suit particular therapeutic applications. The initial

result of this technology was the creation of an entirely new family of

compounds known as super-benzopyrans, hitherto impossible to manufacture

by existing techniques, and displaying a range of anti-cancer functions not

previously experienced.

In the 2 months since the merger, Novogen has been conducting a series of

manufacturing studies designed to strengthen its patent position through

`reduction to practice', a key requirement for sound patent protection. These
studies have focused on the Company's inaugural drug candidate, CS-6, with the

manufacturing process now in place and able to produce the quantities of drug

required for its developmental program.

Provisional patent application No 2012905600 covers the three cornerstones of

patent protection around Novogen's initial family of super-benzopyrans: method

of manufacture, method of use, and composition of matter.

Dr Andrew Heaton, Novogen Chief Scientist, said, " the design and manufacturing

technology that is the basis of the Novogen technology, in our view heralds a new

era in drug discovery, and not just in the oncology field."

He added, "the ability to create a potent anti-cancer drug such as CS-6, and to
then add a further layer of design to improve its ability to attack cancer cells, and

then to add a further design layer to increase the likelihood of it being able to

cross the blood-brain barrier, is a practical example of what is achievable with

this technology."

Professor Graham Kelly, Novogen CEO, said, "lodging this patent application

marks two milestones. The first is our overriding efforts to protect our valuable

intellectual property. The second is that we have achieved the means to
manufacture CS-6 economically and efficiently, something that is essential to our

objective of taking CS-6 into humans with primary brain cancer in 2014.